Ampicillin and Cefepime Combination Therapy
Ampicillin should be added to cefepime (plus metronidazole) when treating critically ill patients with community-acquired intra-abdominal infections who are at high risk for enterococcal infection, including immunocompromised patients or those with recent antibiotic exposure. 1
Primary Indication: Enhanced Enterococcal Coverage
The combination addresses a critical coverage gap. While cefepime provides excellent gram-negative coverage including Pseudomonas aeruginosa, it lacks activity against enterococci. Ampicillin fills this gap specifically for ampicillin-susceptible enterococci 1.
When to Use This Combination
For critically ill patients with community-acquired intra-abdominal infections:
- Cefepime 2 g IV every 8 hours
- Plus metronidazole 500 mg IV every 6 hours
- Add ampicillin 2 g IV every 6 hours if:
- Patient is immunocompromised
- Recent antibiotic exposure documented
- Not already receiving piperacillin-tazobactam or imipenem-cilastatin (which already cover ampicillin-susceptible enterococci) 1
For healthcare-associated intra-abdominal infections in non-critically ill patients at higher risk for MDROs:
- Meropenem 1 g IV every 8 hours plus ampicillin 2 g IV every 6 hours
- Or doripenem 500 mg IV every 8 hours plus ampicillin 2 g IV every 6 hours 1
Dosing Regimens
Adults (normal renal function):
- Cefepime: 2 g IV every 8-12 hours 2
- Ampicillin: 2 g IV every 6 hours (for enterococcal coverage in IAI) 1
- Metronidazole: 500 mg IV every 6 hours (required for anaerobic coverage) 1
Pediatric patients (>2 months):
- Cefepime: 50 mg/kg IV every 8 hours (maximum 2 g/dose) 3, 2
- Ampicillin: 50 mg/kg IV every 6 hours (for IAI) 3
- Metronidazole: Added for anaerobic coverage 3
Clinical Context and Rationale
The 2017 WSES guidelines explicitly state that ampicillin should be considered "if the patients are not being treated with piperacillin-tazobactam or imipenem-cilastatin (active against ampicillin-susceptible enterococci)" 1. This reflects the understanding that certain patient populations—particularly immunocompromised individuals and those with healthcare-associated infections—face higher risk of enterococcal infections that can contribute to treatment failure and mortality.
Important Caveats
Do NOT routinely add ampicillin for:
- Mild-to-moderate community-acquired infections 3
- Patients already receiving piperacillin-tazobactam (which covers enterococci) 1
- Patients receiving imipenem-cilastatin (which covers enterococci) 1
Empiric enterococcal coverage is NOT necessary in most community-acquired intra-abdominal infections in immunocompetent patients 3. The 2010 IDSA/SIS guidelines state clearly: "Empiric coverage of Enterococcus is not necessary in patients with community-acquired intra-abdominal infection" 3.
Alternative Considerations
For severe infections where broader coverage is needed from the start, piperacillin-tazobactam 4.5 g IV every 6 hours provides both gram-negative (including Pseudomonas) and enterococcal coverage without requiring combination therapy 1. This simplifies the regimen while maintaining appropriate spectrum.
Renal Dose Adjustments
Both agents require adjustment in renal impairment. For cefepime with CrCl 30-60 mL/min, reduce to 2 g every 12 hours; for CrCl 11-29 mL/min, reduce to 2 g every 24 hours 2. Ampicillin dosing should similarly be adjusted based on creatinine clearance.
Duration of Therapy
Typical duration is 7-10 days for complicated intra-abdominal infections, though this should be individualized based on source control adequacy and clinical response 1, 3.